Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Julia Sbierski-KindDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-7133-5332
Kelly M CautivoDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-4434-2814
Julia NilssonDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Johanna C WagnerDepartment of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-2999-6900
Madelene W DahlgrenDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-8640-0157
Nathan Ewing CrystalDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-2486-1783
Maria McClaveDepartment of Medicine, Pulmonary Division, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-9255-0936
Nicholas M MrozDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-4781-8518
Marlene GanslmeierInstitute for Diabetes Research and Metabolic Diseases (IDM) of Helmholtz Munich at the University of Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.
Carlos O LizamaCardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94143, USA.
Anna Lu GanDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0009-0002-5178-7352
Peri R MatatiaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-5389-3637
Marcela T TaruselliDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-7965-4335
Anthony A ChangDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-6901-3278
Sofia CaryotakisDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-3522-0022
Claire E O'LearyDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-9052-4593
Maya KotasDepartment of Medicine, Pulmonary Division, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-8102-6346
Jun-Hoe LeeQuantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany.ORCID 0000-0002-6331-3472
Taeeun GuDepartment of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.ORCID 0009-0001-8317-9047
Hyeewon SeoDepartment of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.ORCID 0009-0007-2026-7633
Hyun Je KimDepartment of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.ORCID 0000-0003-4467-0949
Aras N MattisLiver Center, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-5813-164X
Tien PengDepartment of Medicine, Pulmonary Division, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-2226-4635
Richard M LocksleyDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-5468-6867
Ari B MolofskyDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-0764-3175
Funding
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Establishing patient-derived iPSCs as a platform for discovery research in NAFLDRC2DK136052 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JACQUELYN J. MAHER, Aras Nikodemas Mattis · 2023 to 2026
$6.4M
Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5M
Localization and function of tissue type 2 lymphocytes during mixed inflammationR01AI162806 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Ari B Molofsky · 2022 to 2026
Fibroblasts are dynamic structural cells that direct both beneficial tissue repair and pathological organ fibrosis through interactions with tissue-resident type 2 lymphocytes (T2Ls) and type 3/17 lymphocytes (T3Ls). The cytokines interleukin-13 (IL-13) and IL-17A, produced by T2Ls and T3Ls, respectively, are linked to both tissue inflammation and fibrosis, but how their spatial positioning influences beneficial or pathological organ remodeling remains unclear. Using mouse models of liver injury and fibrosis, three-dimensional microscopy, and spatial transcriptomics, we found an accumulation of periportal and fibrotic tract T2Ls, predominantly group 2 innate lymphoid cells (ILC2s), positioned near T3Ls and niche adventitial fibroblasts and adjacent to discrete profibrotic myofibroblasts. Unexpectedly, T2L ablation worsened both carbon tetrachloride- and bile duct ligation-induced liver fibrosis, accompanied by increased IL-17A
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Type 2 lymphocytes restrict type 3 lymphocytes during liver fibrosis and colocalize in fibroblast niches. · full record | OpenQuestion